Returned drug money should not fund waiting list drive
The billions of pounds due to be clawed back from pharma firms under a new NHS pricing deal should not be diverted to help hospitals cut waiting lists, the head of the Association of British Pharmaceutical Industry has urged.
You need to be a subscriber to read more
Subscribe for unlimited access
With a HSJ subscription you’ll unlock:
- All HSJ news by sector, topic & region
- Breaking News announcements
- App for mobile and offline reading
- Comment and Daily Insights newsletters
- Regional roundup newsletters
- 10 expert briefings every fortnight (Premium only)
- Unrestricted access to ‘Ask HSJ’ - AI assistant - AI assistant (Premium only)
Already a subscriber? Sign into your account here